Sanofi's Tolebrutinib Accepted for FDA Review in Non-Relapsing Secondary Progressive Multiple Sclerosis
CompanyDrug

Sanofi’s Tolebrutinib Accepted for FDA Review in Non-Relapsing Secondary Progressive Multiple Sclerosis

Fosun Pharma's 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment
Company

Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment

Burning Rock Reports Q4 Revenue Growth Amid Improved Profitability
Company

Burning Rock Reports Q4 Revenue Growth Amid Improved Profitability

China's 2025 Pharmacopoeia Edition Approved, Set for October 1 Implementation
Policy / Regulatory

China’s 2025 Pharmacopoeia Edition Approved, Set for October 1 Implementation

Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab
Company

Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab

Shanghai Henlius Biotech Receives NMPA Approval for HLX79 in Glomerulonephritis Trial
CompanyDrug

Shanghai Henlius Biotech Receives NMPA Approval for HLX79 in Glomerulonephritis Trial

Chia Tai Tianqing's TQB2210 Approved for Advanced Malignant Tumor Study
CompanyDrug

Chia Tai Tianqing’s TQB2210 Approved for Advanced Malignant Tumor Study

CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access
CompanyDeals

CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access

Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline
Company

Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline

Jiangsu Hengrui Pharmaceuticals Inks Global License Deal with Merck for HRS-5346
CompanyDeals

Jiangsu Hengrui Pharmaceuticals Inks Global License Deal with Merck for HRS-5346

Sichuan Kelun-Biotech Gains NMPA Approval for SKB107 Bone Metastasis Trial
CompanyDrug

Sichuan Kelun-Biotech Gains NMPA Approval for SKB107 Bone Metastasis Trial

Abbisko Therapeutics Receives NMPA Approval for ACH Drug ABSK061
CompanyDrug

Abbisko Therapeutics Receives NMPA Approval for ACH Drug ABSK061